<DOC>
	<DOC>NCT02799914</DOC>
	<brief_summary>Post market clinical follow-up study about the Sinus-venous stent. Patients with venous iliofemoral occlusive disease are treated with the Sinus-venous stent. This observational study will provide 1 year data about safety and efficacy.</brief_summary>
	<brief_title>Evaluation of the Sinus-Venous Stent for the Treatment of Iliofemoral Venous Occlusive Disease</brief_title>
	<detailed_description />
	<mesh_term>Vascular Diseases</mesh_term>
	<criteria>1. Age at study entry is at least 18 years. 2. Patient must sign the informed consent form prior to the indexprocedure. 3. Patient suffers from acute or chronic venous occlusive disease indicated to be treated with a venous stent. 4. Target lesion is located in the femoral vein, common femoral vein, external iliac vein, or common iliac vein. 1. Intolerance to anticoagulant medication. 2. Contraindication for prolonged anticoagulant treatment. 3. Life expectancy less than 1 year. 4. Target vessel has been stented before. 5. Coagulopathy or known uncorrectable bleeding diathesis. 6. Recent (&lt;1 year) pulmonary embolism. 7. Pregnancy. 8. Known hypersensitivity to nitinol and/or nickel. 9. Known to be, or suspected of being unable to comply with the study protocol (e.g. no permanent address, known to be noncompliant or presenting an unstable psychiatric history). 10. Legal incapacity and/or other circumstances rendering the patient unable to understand the nature, scope and possible impact of the study. 11. Patients in custody by juridical order. 12. Patients who do not agree to the transmission of their coded data within the liability of documentation and notification. 13. Close affiliation with the investigational site: e.g. a close relative of the investigator or a possibly dependent person (e.g. employee or student of the investigational site).</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>